文献速递骨质疏松与钙磷/甲状旁腺

MBX 2109——一种每周一次甲状旁腺激素替代治疗前体药物:1期首次人体随机试验

MBX 2109, A Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-In-Human, Randomized Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本研究为1期随机双盲安慰剂对照多次递增剂量试验,纳入健康成人40例,按4:1随机接受MBX 2109(200、400、600、900 μg,n=8)或安慰剂(n=2)皮下注射每周一次共4次。主要终点为安全性和耐受性;MBX 2109组未观察到严重或重度治疗中出现的不良事件,注射部位反应为最常见治疗相关不良事件;MBX 2109半衰期为79至95小时,其脂肪酸酰化生物活性PTH肽半衰期为184至213小时。结论认为MBX 2109耐受良好,长半衰期支持每周一次给药,并确定了未来研究的剂量。

要点

  • MBX 2109组治疗中出现的不良事件发生率为50%至88%,安慰剂组为25%。
  • MBX 2109组未观察到严重或重度治疗中出现的不良事件。
  • MBX 2109半衰期为79至95小时,其生物活性PTH肽半衰期为184至213小时。

核心结论

  • MBX 2109耐受良好,未出现非预期的脱靶安全问题。
  • MBX 2109及其生物活性PTH激动剂的长半衰期和平坦暴露特征支持每周一次给药。
  • 已确定MBX 2109用于未来研究的剂量。

研究设计与样本

  • 1期随机双盲安慰剂对照多次递增剂量试验(NCT05158335),纳入健康成人。
  • 受试者按4:1随机接受MBX 2109(200、400、600、900 μg;n=8)或安慰剂(n=2)皮下注射,每周一次共4次(第1、8、15、22天)。
  • 共40例受试者被随机分配(MBX 2109组n=32,安慰剂组n=8;平均年龄43.3岁;女性22.5%)。
  • 主要终点为安全性和耐受性;关键次要终点为药代动力学和药效动力学。

主要发现

  • 治疗中出现的不良事件在MBX 2109组发生于50%至88%的受试者,在安慰剂组发生于25%的受试者。
  • MBX 2109组未观察到严重或重度治疗中出现的不良事件。
  • 注射部位反应是最常见的治疗相关治疗中出现的不良事件。
  • MBX 2109的半衰期为79至95小时,脂肪酸酰化生物活性PTH肽的半衰期为184至213小时。
  • 脂肪酸酰化生物活性PTH肽暴露呈剂量和时间依赖性增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Hypoparathyroidism denotes parathyroid hormone (PTH) deficiency and impaired mineral metabolism. MBX 2109, a novel prodrug yielding a biologically active PTH peptide agonist (PTH[1-32], extended by a fatty acylated Lys33), is being developed as a long-acting, once-weekly PTH replacement therapy. OBJECTIVE: Here, we report the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MBX 2109 in healthy volunteers. METHODS: This phase 1, randomized, double-blind, placebo-controlled, multiple ascending-dose study (NCT05158335) enrolled healthy adults, who were randomly assigned 4:1 to receive MBX 2109 (200, 400, 600, and 900 μg; n = 8) or placebo (n = 2) by subcutaneous administration once weekly for 4 doses (days 1, 8, 15, and 22). The primary end point was safety and tolerability. Key secondary end points were PK and PD. RESULTS: Overall, 40 participants (MBX 2109 n = 32, placebo n = 8) were randomly assigned (mean age, 43.3 years; 22.5% female). Treatment-emergent adverse events (TEAEs) occurred in 50% to 88% of MBX 2109 groups and in 25% of placebo participants. In the MBX 2109 groups, no severe or serious TEAEs were observed. Injection-site reaction was the most common treatment-related TEAE. The half-lives were 79 to 95 hours for MBX 2109 and 184 to 213 hours for the fatty-acylated biologically active PTH peptide, which showed dose- and time-dependent exposure increases. CONCLUSION: The sustained-action PTH prodrug MBX 2109 was well tolerated with no unexpected, off-target safety issues. The long half-life and flat exposure profile of MBX 2109's biologically active PTH agonist supports once-weekly administration. MBX 2109 doses were identified for future studies.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Carney P, Cutler GB, Schneider K, et al. MBX 2109, A Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-In-Human, Randomized Trial. J Clin Endocrinol Metab. 2025. PMID: 39574220. doi:10.1210/clinem/dgae808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。